New MHRA Research Advances Needle-Free Strep A Vaccine Development

Pioneering research by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), in partnership with the GSK Vaccines Institute for Global Health, has brought a vaccine against Group A Streptococcus (Strep A) closer to reality. Published in Human Vaccines & Immunotherapeutics, the study also shows promise for 'needle-free' vaccines that could be administered nasally or sublingually, generating strong immune responses at mucosal surfaces and throughout the body. There is currently no licensed vaccine for Strep A, which causes hundreds of millions of infections annually.